ArticleParasitology research2015
Nanoparticles in the fight against mosquito-borne diseases: bioactivity of Bruguiera cylindrica-synthesized nanoparticles against dengue virus DEN-2 (in vitro) and its mosquito vector Aedes aegypti (Diptera: Culicidae).
Article in Parasitology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 73 citations in OpenAlex.
- Targeting Dengue Viral Proteins with Eco-Friendly Nanotechnology: A Promising Path for Antiviral Research.Viruses · 2026Review
- Article
- Silver Nanoparticle-Mediated Antiviral Efficacy against Enveloped Viruses: A Comprehensive Review.Global challenges (Hoboken, NJ) · 2025Review
- Biosynthesized Chitosan-Coated Silver Nanoparticles: Insecticide Activity and Sublethal Effects AgainstBiomolecules · 2025Article
- Review
- Termiticidal Effects and Morpho-Histological Alterations in the Subterranean Termite (Nanomaterials (Basel, Switzerland) · 2024Article
- Chemical Constituents and Biological Activities ofMarine drugs · 2024Review
- Updates on Biogenic Metallic and Metal Oxide Nanoparticles: Therapy, Drug Delivery and Cytotoxicity.Pharmaceutics · 2023Review
- Silver Nanoparticles: Review of Antiviral Properties, Mechanism of Action and Applications.Microorganisms · 2023Review
- Review
- Synthesis of new series of quinoline derivatives with insecticidal effects on larval vectors of malaria and dengue diseases.Scientific reports · 2022Article
- Synthesis, Characterization and Biomedical Application of Silver Nanoparticles.Materials (Basel, Switzerland) · 2022Review
- Green Nano-Biotechnology: A New Sustainable Paradigm to Control Dengue Infection.Bioinorganic chemistry and applications · 2022Review
- Recent advances on therapeutic potentials of gold and silver nanobiomaterials for human viral diseases.Current research in chemical biology · 2022Review
- Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections.Biological trace element research · 2021Review
- Antiviral therapies: advances and perspectives.Fundamental & clinical pharmacology · 2021Review
- A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19).Bulletin of the National Research Centre · 2021Review
- Multi-sulfonated ligands on gold nanoparticles as virucidal antiviral for Dengue virus.Scientific reports · 2020Article
- Biological effects of Avicennia marina (Forssk.) vierh. extracts on physiological, biochemical, and antimicrobial activities against three challenging mosquito vectors and microbial pathogens.Environmental science and pollution research international · 2020Article
- Recent Developments in Nanotechnology for Detection and Control ofFrontiers in bioengineering and biotechnology · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 8 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mosquitoes are blood-feeding insects serving as the most important vectors for spreading human pathogens and parasites. Dengue is a viral disease mainly vectored through the bite of Aedes mosquitoes. Its transmission has recently increased in urban and semi-urban areas of tropical and subtropical regions worldwide, becoming a major international public health concern. There is no specific treatment for dengue. Its prevention and control solely depend on effective vector control measures. Mangrove plants have been used in Indian traditional medicine for a wide array of purposes. In this research, we proposed a method for biosynthesis of antiviral and mosquitocidal silver nanoparticles (AgNP) using the aqueous extract of Bruguiera cylindrica leaves. AgNP were characterized using a variety of biophysical analyses, including UV-visible spectrophotometry, Fourier-transform infrared spectroscopy, scanning electron microscopy, and energy-dispersive X-ray spectroscopy. Bruguiera cilyndrica aqueous extract and green-synthesized AgNP were tested against the primary dengue vector Aedes aegypti. AgNP were the most effective. LC50 values ranged from 8.93 ppm (larva I) to 30.69 ppm (pupa). In vitro experiments showed that 30 μg/ml of AgNP significantly inhibited the production of dengue viral envelope (E) protein in vero cells and downregulated the expression of dengue viral E gene. Concerning nontarget effects, we observed that the predation efficiency of Carassius auratus against A. aegypti was not affected by exposure at sublethal doses of AgNP. Predation in the control was 71.81 % (larva II) and 50.43 % (larva III), while in an AgNP-treated environment, predation was boosted to 90.25 and 76.81 %, respectively. Overall, this study highlights the concrete potential of green-synthesized AgNP in the fight against dengue virus. Furthermore, B. cylindrica-synthesized AgNP can be employed at low doses to reduce larval and pupal population of A. aegypti, without detrimental effects of predation rates of mosquito predators, such as C. auratus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.